Poster
32
(#32) Real-World Treatment Persistence to Cariprazine Versus Quetiapine Among Patients With Bipolar I Disorder
Psych Congress 2025
Abstract: Background: There is limited evidence on comparative treatment persistence among atypical antipsychotics (AAs) used for bipolar I (BP-I) disorder. This study evaluated real-world persistence to cariprazine compared with quetiapine among patients with BP-I.
Methods: This real-world retrospective study assessed treatment persistence among commercially-insured adults with BP-I in the Merative™ MarketScan® Database (01/2015-03/2024) with ≥2 dispensings of cariprazine or quetiapine. Patients with evidence of low-dose quetiapine (≤100 mg/day) on initial claim were excluded. Baseline characteristics between cohorts were balanced using inverse probability of treatment weighting based on the propensity score. Kaplan-Meier analyses and Cox proportional hazards models were used to assess and compare persistence up to 12 months after initiation, defined as time on treatment without discontinuation (gap exceeding 60 days) in weighted cariprazine and quetiapine cohorts.
Results: A total of 1,482 patients with BP-I initiated cariprazine and 3,255 patients initiated quetiapine, of which 1,034 (31.8%) patients who initiated quetiapine >100 mg/day were included. Baseline characteristics were well-balanced between weighted cohorts. Median persistence was 228 days for cariprazine and 180 days for quetiapine. The proportion of patients persistent to cariprazine and quetiapine was 58.6% and 50.9%, respectively, at 6 months, and 37.4% and 34.7%, respectively, at 12 months. Patients initiating cariprazine were 15% less likely to discontinue treatment compared with patients taking quetiapine at 12 months following initiation (weighted hazard ratio for discontinuation [95% CI]: 0.85 [0.75, 0.97], P=.02).
Conclusions: In this real-world study, cariprazine demonstrated higher persistence versus quetiapine among commercially-insured patients with BP-I.
Short Description: This real-world retrospective claims database study compared the persistence (i.e., time on treatment) of cariprazine and quetiapine treatment among commercially insured patients with bipolar I disorder (BP-I). Patients with BP-I initiating cariprazine had better persistence versus quetiapine.
Name of Sponsoring Organization(s): AbbVie Inc.
Methods: This real-world retrospective study assessed treatment persistence among commercially-insured adults with BP-I in the Merative™ MarketScan® Database (01/2015-03/2024) with ≥2 dispensings of cariprazine or quetiapine. Patients with evidence of low-dose quetiapine (≤100 mg/day) on initial claim were excluded. Baseline characteristics between cohorts were balanced using inverse probability of treatment weighting based on the propensity score. Kaplan-Meier analyses and Cox proportional hazards models were used to assess and compare persistence up to 12 months after initiation, defined as time on treatment without discontinuation (gap exceeding 60 days) in weighted cariprazine and quetiapine cohorts.
Results: A total of 1,482 patients with BP-I initiated cariprazine and 3,255 patients initiated quetiapine, of which 1,034 (31.8%) patients who initiated quetiapine >100 mg/day were included. Baseline characteristics were well-balanced between weighted cohorts. Median persistence was 228 days for cariprazine and 180 days for quetiapine. The proportion of patients persistent to cariprazine and quetiapine was 58.6% and 50.9%, respectively, at 6 months, and 37.4% and 34.7%, respectively, at 12 months. Patients initiating cariprazine were 15% less likely to discontinue treatment compared with patients taking quetiapine at 12 months following initiation (weighted hazard ratio for discontinuation [95% CI]: 0.85 [0.75, 0.97], P=.02).
Conclusions: In this real-world study, cariprazine demonstrated higher persistence versus quetiapine among commercially-insured patients with BP-I.
Short Description: This real-world retrospective claims database study compared the persistence (i.e., time on treatment) of cariprazine and quetiapine treatment among commercially insured patients with bipolar I disorder (BP-I). Patients with BP-I initiating cariprazine had better persistence versus quetiapine.
Name of Sponsoring Organization(s): AbbVie Inc.
